Back to results
US 12,403,155 B2Granted
Methods and compositions for the activation of gamma-delta T-cells
AssigneeAmerican Gene Technologies International Inc.
InventorsCharles David Pauza, Haishan Li, Tyler Lahusen, Mei-Ling Liou
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta T-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.
Claims16
A pharmaceutical combination, comprising:
- (a) a bisphosphonate drug;
- and
- (b) a lentiviral particle comprising an envelope protein and a therapeutic vector comprising:
- an EF-1 alpha promoter and
- at least one encoded shRNA or microRNA that, when expressed, inhibits production of farnesyl diphosphate synthase (FDPS)
- wherein the bisphosphonate drug and lentiviral particle are administered together or separately,
- wherein the at least one encoded shRNA or microRNA comprises a sequence having at least 80 percent identity with SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, or SEQ ID NO:
- 10.
14 more elements
A pharmaceutical combination, comprising:
- (a) a bisphosphonate drug;
- and
- (b) a lentiviral particle comprising an envelope protein and a therapeutic vector comprising:
- at least one encoded shRNA or microRNA that, when expressed, inhibits production of farnesyl diphosphate synthase (FDPS) and activates a GD T cell wherein the bisphosphonate drug and lentiviral particle are administered together or separately,
- wherein the at least one encoded shRNA or microRNA comprises a sequence having at least 80 percent identity with SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, or SEQ ID NO:
- 10.
12 more elements
A method of treating a cancer in a subject in need thereof, using an immunotherapy-based composition, the method comprising:
- (a) administering a therapeutically-effective amount of an bisphosphonate drug to the subject;
- and
- (b) administering a therapeutically-effective amount of the immunotherapy-based composition to the subject,
- wherein the immunotherapy-based composition comprises a lentiviral particle, the lentiviral particle comprising an envelope protein and a therapeutic vector comprising:
- an EF-1 alpha promoter;
- and,
- at least one encoded shRNA or microRNA that, when expressed, inhibits production of farnesyl diphosphate synthase (FDPS),
- wherein the at least one encoded shRNA or microRNA comprises a sequence having at least 80 percent identity with SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, or SEQ ID NO:
- 10.
15 more elements
A method of treating a cancer in a subject in need thereof, using an immunotherapy-based composition, the method comprising:
- (a) administering a therapeutically-effective amount of an bisphosphonate drug to the subject;
- and
- (b) administering a therapeutically-effective amount of the immunotherapy-based composition to the subject,
- wherein the immunotherapy-based composition comprises a lentiviral particle, the lentiviral particle comprising an envelope protein and a therapeutic vector comprising:
- at least one encoded shRNA or microRNA that, when expressed, inhibits production of farnesyl diphosphate synthase (FDPS) and activates a GD T cell,
- wherein the at least one encoded shRNA or microRNA comprises a sequence having at least 80 percent identity with SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, or SEQ ID NO:
- 10.
13 more elements
Dependencies are inferred from the claim text.